Last reviewed · How we verify
Motrin/Percocet/Dilaudid for breakthrough
Motrin/Percocet/Dilaudid for breakthrough is a Combination analgesic regimen (NSAID + opioid + potent opioid) Small molecule drug developed by University Hospitals Cleveland Medical Center. It is currently FDA-approved for Breakthrough pain management in opioid-tolerant patients, Moderate-to-severe acute pain.
This is a combination regimen using ibuprofen (NSAID), oxycodone/acetaminophen (opioid analgesic), and hydromorphone (potent opioid) for managing breakthrough pain.
This is a combination regimen using ibuprofen (NSAID), oxycodone/acetaminophen (opioid analgesic), and hydromorphone (potent opioid) for managing breakthrough pain. Used for Breakthrough pain management in opioid-tolerant patients, Moderate-to-severe acute pain.
At a glance
| Generic name | Motrin/Percocet/Dilaudid for breakthrough |
|---|---|
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Combination analgesic regimen (NSAID + opioid + potent opioid) |
| Target | Cyclooxygenase (COX-1/COX-2); mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Motrin (ibuprofen) is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes to reduce inflammation and pain. Percocet (oxycodone/acetaminophen) combines an opioid mu-receptor agonist with acetaminophen for moderate-to-severe pain. Dilaudid (hydromorphone) is a potent mu-opioid receptor agonist used for severe breakthrough pain. Together, this multimodal approach targets pain through both inflammatory and opioid pathways.
Approved indications
- Breakthrough pain management in opioid-tolerant patients
- Moderate-to-severe acute pain
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Respiratory depression
- Gastrointestinal upset (from NSAID)
Key clinical trials
- ICE-T Pain Regimen for Total Laparoscopic Hysterectomy (PHASE4)
- Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motrin/Percocet/Dilaudid for breakthrough CI brief — competitive landscape report
- Motrin/Percocet/Dilaudid for breakthrough updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI
Frequently asked questions about Motrin/Percocet/Dilaudid for breakthrough
What is Motrin/Percocet/Dilaudid for breakthrough?
How does Motrin/Percocet/Dilaudid for breakthrough work?
What is Motrin/Percocet/Dilaudid for breakthrough used for?
Who makes Motrin/Percocet/Dilaudid for breakthrough?
What drug class is Motrin/Percocet/Dilaudid for breakthrough in?
What development phase is Motrin/Percocet/Dilaudid for breakthrough in?
What are the side effects of Motrin/Percocet/Dilaudid for breakthrough?
What does Motrin/Percocet/Dilaudid for breakthrough target?
Related
- Drug class: All Combination analgesic regimen (NSAID + opioid + potent opioid) drugs
- Target: All drugs targeting Cyclooxygenase (COX-1/COX-2); mu-opioid receptor
- Manufacturer: University Hospitals Cleveland Medical Center — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Breakthrough pain management in opioid-tolerant patients
- Indication: Drugs for Moderate-to-severe acute pain
- Compare: Motrin/Percocet/Dilaudid for breakthrough vs similar drugs
- Pricing: Motrin/Percocet/Dilaudid for breakthrough cost, discount & access